98%
921
2 minutes
20
Background: To reduce complications associated with metal occluders, bioabsorbable occluders have been implanted for perimembranous ventricular septal defects (VSDs) via transthoracic approach. This study investigates the feasibility of echocardiography-guided percutaneous closure of perimembranous VSDs in children using bioabsorbable occluders, along with its 1-year follow-up outcomes.
Aims: To evaluate the feasibility and 1-year outcomes of echocardiography-guided percutaneous closure of perimembranous VSDs using bioabsorbable occluders in children.
Methods: Between April 2023 and March 2024, consecutive children with perimembranous VSDs underwent percutaneous closure using bioabsorbable occluders under echocardiography guidance alone were enrolled. Procedural success was defined as percutaneous device implantation under sole ultrasound guidance with residual shunt ≤ 2 mm and no severe in-hospital complications. Preoperative, intraoperative, and follow-up data were prospectively collected and analyzed.
Results: The study cohort comprised 14 children, including three with a subaortic rim ≤ 3 mm and one with a distance of ≤ 1 mm between the VSD and the tricuspid septal leaflet. All procedures were successful. Vascular access was via the femoral artery in six patients (42.9%) and femoral vein in eight patients (57.1%). No major complications occurred. A 2 mm residual shunt was noted in one patient (7.1%) and remained unchanged during the follow-up period. While new-onset mild/moderate tricuspid regurgitation occurred in three patients (21.4%), all cases showed improvement over time. At 1 year, no new onset aortic regurgitation or complete heart block were reported, and the occluders were largely absorbed.
Conclusion: Percutaneous closure of perimembranous VSDs in children using bioabsorbable occluders under echocardiography guidance is feasible, with promising 1-year outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412347 | PMC |
http://dx.doi.org/10.1002/ccd.70022 | DOI Listing |
World J Cardiol
July 2025
Department of Cardiovascular Medicine, Fuwai Yunnan Hospital, Chinese Academy Medical Sciences, Kunming 650000, Yunnan Province, China.
This review comprehensively examines acute myocardial infarction with ventricular septal rupture (VSR), a rare yet lethal complication. We analyze its epidemiological, pathophysiological, clinical, and therapeutic aspects, emphasizing innovative strategies like bioabsorbable occluders and tissue engineering to reduce complications and improve prognosis. The integration of artificial intelligence and big data analytics for treatment decision-making and personalized surgical timing models is highlighted as transformative.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Department of Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Background: To reduce complications associated with metal occluders, bioabsorbable occluders have been implanted for perimembranous ventricular septal defects (VSDs) via transthoracic approach. This study investigates the feasibility of echocardiography-guided percutaneous closure of perimembranous VSDs in children using bioabsorbable occluders, along with its 1-year follow-up outcomes.
Aims: To evaluate the feasibility and 1-year outcomes of echocardiography-guided percutaneous closure of perimembranous VSDs using bioabsorbable occluders in children.
Front Med (Lausanne)
July 2025
Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Background: Transcatheter closure of patent foramen ovale (PFO) has shown potential therapeutic benefits for clinical symptoms in selected patients with migraine. Nevertheless, the comparative effectiveness and safety of traditional nitinol vs. fully biodegradable occluders remain to be fully elucidated and warrant further investigation.
View Article and Find Full Text PDFFront Bioeng Biotechnol
February 2025
Biomedical Engineering and Physiology, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, United States.
Introduction: Flow diverters are specialized stents used to treat intracranial aneurysms. Bioresorbable flow diverters (BRFDs) have been proposed as the next-generation of flow diverter technology. BRFDs aim to occlude and heal the aneurysm before safely dissolving into the body, mitigating complications associated with the permanent presence of conventional flow diverters.
View Article and Find Full Text PDF